Name
InVitria
What We Do
InVitria is a global leader in developing high-performance, animal-free recombinant proteins and media supplements, uniquely engineered to optimize biomanufacturing processes. With a dedicated commitment to purity, consistency, and regulatory compliance, InVitria's solutions drive scientific innovation across cell therapy, gene therapy, regenerative medicine, vaccines, and biologics manufacturing.
Our portfolio includes recombinant Human Serum Albumin (rHSA), transferrin, lactoferrin, Leukemia Inhibitory Factor (LIF), and complete chemically defined media formulations. Our recombinant products, including Cellastim-S, Exbumin, Optibumin, Optiferrin, and Lacromin, deliver unmatched consistency and performance, overcoming common challenges associated with serum-derived supplements such as variability, risk of contaminants, and supply chain unpredictability.
InVitria's products are leveraged by leading biopharma companies globally, proven in FDA and EMA-approved therapeutics, including vaccines such as Merck's ERVEBO®. Our cGMP-compliant and ISO 9001-certified manufacturing facilities ensure stringent quality control, providing customers with reliable, scalable solutions that accelerate clinical development and commercialization.
Visit us at ASGCT booth #646 to learn how InVitria's recombinant solutions enable enhanced cell growth, improved transfection efficiency, increased viral vector yield, and superior product stability. Engage with our scientific experts to explore innovative ways to optimize your biologics workflow and transition seamlessly to animal-origin-free alternatives that meet the demands of today's advanced biomanufacturing landscape.
Discover why global innovators choose InVitria to define the next generation of cell culture performance.
Performance. Defined.
Our portfolio includes recombinant Human Serum Albumin (rHSA), transferrin, lactoferrin, Leukemia Inhibitory Factor (LIF), and complete chemically defined media formulations. Our recombinant products, including Cellastim-S, Exbumin, Optibumin, Optiferrin, and Lacromin, deliver unmatched consistency and performance, overcoming common challenges associated with serum-derived supplements such as variability, risk of contaminants, and supply chain unpredictability.
InVitria's products are leveraged by leading biopharma companies globally, proven in FDA and EMA-approved therapeutics, including vaccines such as Merck's ERVEBO®. Our cGMP-compliant and ISO 9001-certified manufacturing facilities ensure stringent quality control, providing customers with reliable, scalable solutions that accelerate clinical development and commercialization.
Visit us at ASGCT booth #646 to learn how InVitria's recombinant solutions enable enhanced cell growth, improved transfection efficiency, increased viral vector yield, and superior product stability. Engage with our scientific experts to explore innovative ways to optimize your biologics workflow and transition seamlessly to animal-origin-free alternatives that meet the demands of today's advanced biomanufacturing landscape.
Discover why global innovators choose InVitria to define the next generation of cell culture performance.
Performance. Defined.
Founded
2009
Website
Categories (1000)
Innovation Lab/R&D, CAR T, Cell Therapy, Gene Therapy, Innovation Lab/R&D, CAR T/Oncolytics, Cell Processing, Cell Product Manufacturing, Formulation Development, Gene Therapy, Proteins - Recombinant, Vaccines, Viral Vector Manufacturing - Adeno-Associated Virus, Viral Vector Manufacturing - Adenovirus, Viral Vector Manufacturing - Lentivirus, Biologics, CAR T/ Oncolytics Specialty, Cell Therapy, Gene Therapy, Pre-Clinical Research, Viral Vectors, Federal, Local, Manufacturing Enabling Technology, Platform Technology, Supply Chain/Logistics, Blood/Plasma Products and Services, Closed System Consumables, Cytokines & Growth Factors, Growth & Culture Media, Plasma Proteins, Purification Reagents
Phone
1-800-916-8311
Address
2718 Industrial Drive
Junction City, KS 66441
United States
Junction City, KS 66441
United States
Facebook
Twitter
